BioCentury
ARTICLE | Company News

Sosei gets option to acquire MiNA

May 5, 2017 1:38 AM UTC

Sosei Group Corp. (Tokyo:4565) invested £35 million ($45.2 million) in small activating RNA company MiNA Therapeutics Ltd. (London, U.K.) in exchange for a 25.6% equity stake and an exclusive option to acquire the company.

In the structured deal, Sosei may opt to acquire additional equity in MiNA in phases, which are tied to milestones in the Phase I/IIa OUTREACH trial evaluating MTL-CEBPA to treat hepatocellular carcinoma (HCC). The companies expect those milestones to occur within 18 months. Data are expected next year...